The commercially available rFVIII proteins are produced in mammalian non-human or human cell lines; the host cell line and culture conditions influence the posttranslational modification of the expressed protein. 3 The licensed rFVIII products are produced from either a full-length gene, resulting in a heterogeneous mixture of heavy chains (HCs) with different lengths of the B-domain attached; B-domain deleted (BDD); or from a B-domain-truncated construct with 21 amino acids of the naturally occurring B-domain attached. 3, 4 Previous studies reported differences between the quality of the full-length and B-domain-modified rFVIII preparations, that is in relation to the presence of aggregates and subvisible particles. [5] [6] [7] Limited information is available on the contribution of different aggregates or aggregate characteristics in antibodymediated adverse events. 8 Although it is known that FVIII immunological reactions are highly complex, questions remain on the potential impact of these protein degradation products in the protein formulations. 9, 10 Regulatory agencies place increased emphasis on the potential clinical implications of subvisible particles and recommend careful analysis to characterize the particles in therapeutic protein products. 11, 12 The precise mechanism by which subvisible particles form is unknown, but researchers consider freezing, oxidation, elevated temperatures, exposure to light, mechanical stress, stress during purification, production, storage and transport to be major contributing factors. [13] [14] [15] [16] [17] [18] Materials in contact with the product, such as the product vial components, can also affect particle formation. 17 Advances in analytical technologies have enabled quantification and examination of the morphology of these particles. 
| ME THODS

| rFVIII products and sample preparation
Six commercially available rFVIII products were analysed in the study; three BDD or truncated rFVIII products (turoctocog alfa, simoctocog alfa and moroctocog alfa) and three full-length rFVIII products (octocog alfa FS and two octocog alfa) (Table 1) . 3, 19, 20 All products were reconstituted and prepared for needle injection per the manufacturers' prescribing information. As the indicated diluent volume was not identical for all products, not all of the reconstituted products had the same concentration (Table 1) . Where appropriate, data were corrected for this volume/concentration difference.
Preparation included passage through the butterfly needle for all products; octocog alfa produced in Chinese hamster ovary (CHO)
TA B L E 1 Licensed rFVIII products analysed in this study 3, 19, 20 
| Reverse-phase HPLC (RP-HPLC)
FVIII products were analysed (10 μL of a 0.5 mg mL 
| Liquid chromatography-mass spectrometry (LC-MS)
Sulphation at Tyr-1680 was monitored using LC-MS. Samples were trypsin-digested and examined on an Orbitrap Velos LC-MS/MS (Thermo Scientific, Fisher Scientific UK Ltd, Loughborough, UK). peptides. Data were processed with Pinpoint 1.1 software (Thermo Scientific) using integration of peak areas performed on non-smoothed data. Based on the signal intensities from synthetic peptides, the detection limit of non-sulphated tyrosine was estimated to be 0.5%.
| Ion-exchange HPLC (IE-HPLC)
Samples for carbohydrate analysis were buffer-exchanged to 10 mM Tris, pH 7.5 using an Amicon Ultra centrifugal filter (MerckMillipore, Billerica, MA, USA). Samples were digested with 1U PNGase F (Roche, Basel, Switzerland), and the released glycans precipitated using ice-cold ethanol and labelled by 2-aminobenzamide (2-AB) as described. 21 per the manufacturer's instructions. Separation was carried out by IE-HPLC as described. 22 Eluent A was 150 mM NaOH, eluent B was 150 mM NaOH and 300 mM sodium acetate. The chromatogram was developed using linear gradient from 0% to 65% eluent B over 52 minutes, followed by 40-minute regeneration of the column at 100% eluent B. The flow was 0.5 mL min −1 .
| Micro-flow imaging (MFI)
MFI was performed as described. 23 Briefly, a MFI 5200 (Protein Simple, Ottawa, Ontario, Canada) was used with MFI View System Software v.2-R4.1.1.41.4953. Samples of 0.35 mL with a 0.1 mL prerun were analysed in triplicate at a flow rate of 0.17 mL min −1 . The extracted particle images were analysed using in-house-developed software. 24 The numbers of particles/mL were grouped according to particle size. A complementing image analysis was performed using an in-house mathematical algorithm 25 to filter out silicone-like particles per their well-defined morphology (particle circularity and transparency).
| SE-HPLC
SE-HPLC measurements were performed using miniDAWN TREOS 
| RE SULTS
| Structural comparison of rFVIII products
The structural and chemical heterogeneity of the rFVIII products was assessed by RP-HPLC. Heterogeneity with regard to HC components was observed for all rFVIII products (Figure 1 ).
Turoctocog alfa showed the expected components based on its 26 For octocog alfa (CHO), a specific light chain component containing part of the B-domain was observed. In general, the B-domain-modified products (turoctocog alfa, simoctocog alfa and moroctocog alfa) were more homogenous vs the full-length products (Figure 1 ).
| Sulphation at Tyr-1680
Tyr-1680 sulphation was quantified by LC-MS (Table 2) . Turoctocog alfa and simoctocog alfa (B-domain-modified products) displayed the most complete sulphation (>99.5%), while octocog alfa (modified BHK) and octocog alfa (CHO) (full-length products) showed <90% sulphation at Tyr-1680 (Table 2 ). However, analyses of the remaining full-length and BDD products showed no clear correlation between structure in terms of B-domain-modified and Tyr-1680 sulphation.
| N-linked glycan analysis
N-linked glycans from different rFVIII products were analysed using IE-HPLC. Generally, turoctocog alfa had a carbohydrate profile similar to that of moroctocog alfa, octocog alfa FS, octocog alfa (modified BHK) and octocog alfa (CHO) (Figure 2 ). In particular, moroctocog alfa, octocog alfa FS and octocog alfa (CHO) contained structures similar to turoctocog alfa, while octocog alfa (modified BHK) contained more charged species, likely tri-and tetra-antennary structures, vs turoctocog alfa. On the other hand, the carbohydrate profile of simoctocog alfa was different vs the others, consisting of mainly neutral structures, high mannoses and neutral complex structures (structures generally eluting before 25 minutes) (Figure 2 ). 
TA B L E 2 Sulphation at tyrosine-1680 as determined by LC-MS
| Subvisible particle analysis
MFI analysis showed a large variation in subvisible particle concentration between rFVIII products ( Figure 3A) . It was observed that turoctocog alfa and simoctocog alfa had the lowest number of particles (1000-1600 and 1800-2400 particles/100 IU, respectively) ( Figure 3A) . Octocog alfa FS, octocog alfa (modified BHK) and octocog alfa (CHO) had slightly higher levels of protein particles (1800-10 000, 5300-9100 and 3100-8400 particles/100 IU, respectively), while moroctocog alfa had the highest level of particles (5900-38 300 particles/100 IU) ( Figure 3A ). Image analysis identified some of the particles to have distinct silicone-like particle morphology (particle circularity and transparency); example images of the products with the lowest and highest number of particles are shown (turoctocog alfa and moroctocog alfa, respectively) ( Figure 3B ). Application of a mathematical filter for removal of the silicon-like morphology particles from the data set ( Figure 3B) reduced the number of subvisible particles in all rFVIII products ( Figure 3C) ; however, ranking of products with respect to subvisible particle concentration per IU remained the same after removal of silicone-like particles, with moroctocog alfa having the highest and simoctocog alfa and turoctocog alfa having the lowest concentration of particles. In addition, more than one lot was analysed for turoctocog alfa, moroctocog alfa, octocog alfa FS and octocog alfa (CHO), with a similar level of particles observed between different lots (data not shown).
| HMWP content
The rFVIII products were analysed by SE-HPLC to investigate the presence of protein aggregates. Moroctocog alfa had the highest content of HMWP species; large protein aggregates eluted with a retention time of about 17 minutes ( Figure 4A,B) . The chromatograms further indicated that octocog alfa FS had a higher amount of HMWP species vs the other rFVIII products tested, and that turoctocog alfa had the lowest HMWP content ( Figure 4A,B) . A very high SLS signal was obtained for moroctocog alfa (Figure 4C ), reiterating not only the finding that this product had the highest content of protein aggregates, but also suggesting that moroctocog alfa contained larger particles or aggregates (proteinaceous or not) vs the other rFVIII products tested.
The UV-SE-HPLC data also showed that the full-length rFVIII products 
| D ISCUSS I ON
In this study, we compared the molecular structure of six commercially available rFVIII products. The presence of subvisible particles and pro- Moreover, the three products produced in CHO cells (turoctocog alfa, moroctocog alfa and one of the octocog alfa products) displayed F I G U R E 2 N-linked glycans from different recombinant FVIII products were analysed using ion-exchange high-performance liquid chromatography varying degrees of sulphation ranging from the highest to lowest detected (Table 2) , in agreement with previous findings for turoctocog alfa and octocog alfa (CHO). 28 The use of HEK cells to produce simoctocog alfa is the likely reason this product has a different glycan structure, with more neutral structures, compared with the CHO-and BHK-derived recombinant products.
Indications that protein aggregation and particle formation play a role in triggering immunogenicity reactions have prompted regulatory authorities to request more careful monitoring of these particles in therapeutic products. 
| CON CLUS IONS
Overall, no correlation between molecular structure (ie whether a rFVIII product had full-length B-domain, was BDD or truncated) F I G U R E 3 The concentration of subvisible particles as determined by micro-flow imaging. A, Concentration (per 100 IU) of subvisible particles in rFVIII products. Average of at least three individual vial measurements is shown for each product. Range (in particles/100 IU): turoctocog alfa (1000-1600); simoctocog alfa (1800-2400); moroctocog alfa (5900-38 300); octocog alfa FS (1800-10 000); octocog alfa (modified BHK) (5300-9100); octocog alfa (CHO) (3100-8400). B, Particle images captured via flow imaging before and after mathematical removal of silicon-like particles. Representative images for turoctocog alfa and moroctocog alfa are shown. C, Mathematical removal of silicone-like particles in rFVIII products. Average of at least three individual vial measurements is shown for each product. Range (in particles/100 IU): turoctocog alfa (20-60); simoctocog alfa (20) (21) (22) (23) (24) (25) ; moroctocog alfa (350-2600); octocog alfa FS (60-325); octocog alfa (modified BHK) (80-445); octocog alfa (CHO) (40-110). *Number of subvisible particles/100 IU is used instead of particles/volume due to differences in reconstitution volume of the rFVIII products (see Table 1 ). FVIII, factor VIII; rFVIII, recombinant FVIII and the presence of subvisible particles or HMWP content was observed. The observed dissimilarities among products may be related to production and product handling differences. In this study, turoctocog alfa, like simoctocog alfa, had one of the lowest concentrations of subvisible particles and HMWP and displayed high sample homogeneity. Given the potential clinical implications of protein aggregates, it is important to understand these issues and to reduce the risk to product quality for every therapeutic protein product. 
